Types segmentation categorizes the Biologics Safety Testing Service market into three functional groups: Safety‑focused testing, Efficacy‑focused testing, and Quality‑control testing. Safety‑focused testing, representing roughly 45 % of service spend, includes toxicology, immunogenicity, sterility and endotoxin assays that assess adverse‑event risk across all biologic modalities. Efficacy‑focused testing, about 30 % of the market, comprises pharmacodynamics, biodistribution and potency assays that verify therapeutic activity, especially for cell and gene therapies. Quality‑control testing, contributing the remaining 25 %, encompasses analytical methods such as purity, aggregation, and vector genome integrity assessments required for batch release and regulatory compliance. Each type contributes distinct revenue streams, yet they overlap across applications; for example, sterility testing appears in both vaccine and cell‑therapy segments. Understanding this market taxonomy enables precise allocation of resources and forecasting of growth trends within the Biologics Safety Testing Service market.